论文部分内容阅读
目的:比较标准剂量美罗华与小剂量美罗华治疗原发免疫性血小板减少症(ITP)中的临床疗效及安全性。方法:选取哈尔滨医科大学附属第一、第二医院自2010年-2015年常规治疗无效的原发免疫性血小板减少症(ITP)患者,共18例,分为两个实验组,分别给予应用标准剂量美罗华(375 mg/m~2,每周1次,共4次),患者8例,小剂量美罗华(每次100mg,每周1次,共4次),患者10例,观察两组患者临床效果、治疗前后血小板水平及不良反应的发生情况。结果:小剂量美罗华治疗4周后有效率较标准剂量无明显差别(P>0.05);小剂量美罗华治疗ITP不良反应率相对标准剂量要显著降低低(P<0.05)。结论:小剂量美罗华治疗原发免疫性血小板减少症(ITP)的临床疗效与标准剂量美罗华相当,但安全性更高。
Objective: To compare the clinical efficacy and safety of standard doses of rituximab and low-dose rituximab in the treatment of primary immune thrombocytopenia (ITP). Methods: A total of 18 patients with primary immune thrombocytopenia (ITP) who failed routine therapy from 2010 to 2015 in the First and Second Affiliated Hospital of Harbin Medical University were selected and divided into two experimental groups, Rituximab (375 mg / m 2, once a week, 4 times), 8 patients, low dose rituximab (100mg once a week for 4 times), 10 patients were observed in both groups Clinical effect, platelet level before and after treatment and the incidence of adverse reactions. Results: After 4 weeks of low-dose rituximab treatment, the effective rate was not significantly different from the standard dose (P> 0.05). Low-dose rituximab treatment of ITP adverse reaction rate was significantly lower than the standard dose (P <0.05). Conclusions: The clinical efficacy of low-dose rituximab in the treatment of idiopathic thrombocytopenia (ITP) is comparable to the standard dose of rituximab but is more safe.